of the IL-3 promoter were footprinted in both cell lines. Somewhat surprisingly, the clearest evidence of site occupancy after stimulation was not over previously recognized regulatory sites. Instead, in vivo footprinting highlighted three sites: a CACC repeat whose function is unclear, a conserved cytokine promoter element (CK-;?/GATA) whose role in regulating IL-3 expression could not be established in previous studies: and lastly a region that had been overlooked using conventional approaches. Here we report on the characterization of this region, or IF-lIL3 for in vivo footprintand show that it is necessary but not sufficient for IL-3 expression.
MATERIALS AND METHODS

Cell Line and Cell Activation
The gibbon T-cell line MLA l a L 4 and human Jurkat T cells were maintained in 5% COz at 37°C in RPM1 medium supplemented with 10% fetal calf serum. MLA 144 cells were activated by the addition of 12-myristate, -13 acetate (PMA) at a final concentration of 10 ng/mL for the indicated period (9 hours). Jurkat cells were stimulated by the addition of PMA (10 ng/mL final) and ionomycin (0.5 pmoV
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Cloning c$ the Gibbon IL-3 Promoter
MLA 144 genomic DNA was used as a template for specific polymerase chain reaction (PCR) amplification of the first 400 nt of the IL-3 promoter. The S' primer was a guessmer based on a region starting at -414 in the human pr~moter.'~ The 3' primer was based on available sequence and included the initiation codon of the gibbon cDNA.' Primers were as follows: S' primer: S'-GGGAAGCTTGTT-CCAGTGGCCTCCTGGCC-3': 3' primer: S'-GGCAGCTCATGT-'ITGGA-3'. Two independent clones from the same amplification and one clone from an independent amplification reaction were sequenced. All three clones were identical. Control reactions in which one of the primers or the template DNA was omitted were negative.
Methylation and Isolation of Genomic DNA
After stimulation or mock-treatment of MLA 144 and Jurkat cells, cultures were centrifuged, resuspended in spent medium, and methylated in vivo with dimethylsulfate (DMS) (0.5% final concentration) for 4 minutes at 20°C. The methylation reaction was stopped by adding ice-cold phosphate-buffered saline (PBS) to the cells. Cells were collected and the pellet was washed once with PBS, before DNA was extracted. A control culture of unstirnulated MLA 144 cells was used for isolation of protein free-DNA and methylation of DNA in vitro. In vitro DMS methylation was performed according to Maxam and Gilbert." In vivo-methylated DNA and control DNA methylated in vitro were prepared according to Strauss et al."
Purine-specijc DNA Cleavage and In Vivo Footprinting
Purine specific (G > A) DNA cleavage was performed as described.'? Ligation-mediated PCR (LMPCR) of the proximal region of the 1L-3 promoter was according to the method of Mueller and Wold" with the modification of Strauss et al."
LMPCR Oligonucleotide Primers
Oligonucleotides were obtained from the Dana-Farber Cancer Institute oligonucleotide core facility, deprotected in hot ammonia, and gel purified before use. For top-strand LMPCR, gibbon (gi) and human (hu) specific primer sets were used for the Sequenase (US Biochemicals [USB], Cleveland, OH) extension reaction (primer l), the Taq PCR amplification reaction (primer 2), and the Taq labeling reaction (primer 3). Primer sets are as follows: gi.1: S'-GAAGA-GTTGGCAACAGCCTCC-3'; gi.2: S'-CAGCCTCCCGCCTTA-TATGTGCAGC-3'; gi.3: S'-CAGCCTCCCGCCTTATATGTGC-AGCAGG-3'; hu.1: 5"GAAGAGTTGGCAACAACCTC-3'; hu.2:
5"CAACCTCCCGCCTTATATGTGCAGC-3'; hu.3: 5"CAACCT-CCCGCCTTATATGTGCAGCAGC-3'.
Electroporation, Reporter Gene Constructs, and RNase Protection
MLA cells, 4 X lo', were electroporated with SO pg of reporter gene plasmid DNA, using a ProGenetor I1 apparatus (Hoefer Scientific Instruments, San Francisco, CA) set at 275 V, 960 pF. Thirtysix to 40 hours after electroporation, MLA 144 cells were stimulated with PMA for 9 hours, and total RNA was isolated as described?
Constructs. The reporter gene constructs -61/IW", -I 73/IL3', and -31YIL3" have been described." -31S(IF-I*c)/IL3x was obtained by selectively mutating guanines -139, -1 37, and -136 in the human -315 IL-3 promoter fragment to cytosines. Mutagenesis was performed using standard PCR methodology. The top and bottom oligonucleotides used for mutagenesis (mutated residues underlined) were: IF-lG*-top: 5'-ATAATTACGTCT~T~TTTT-CTATGGAG-3'; IF-lGC-bottom: 5"CTCCATAGAAAAGGAG-AGACGTAA'ITAT-3'.
-173(IF-IGd")/Iw^ was derived from -315(IF-1G+c)/IL3' by truncating the promoter fragment of the latter at a ScaI site. -1431 IL3' was obtained as follows. An IL-3 promoter fragment (-1 to -143) was amplified by PCR. This fragment was digested with Hind111 (this site was introduced immediately upstream of -143 by the 5' primer) and SmaI (position -61 in the human IL-3 promoter). After digestion, the DNA was ligated into the SmuI site (-61) and a 5' Hind111 cloning site of the IL-3 promoter in our reporter gene constructs.' Sequence for the promoters in the -31S(1F-lG'(')/IL3', -173(IF-lG+(')/IL3', and -143/IL3" was confirmed by DNA sequencing.
RNuse protection. Expression of the reporter gene constructs was measured by an RNase protection assay. For each construct, 25 pg of total RNA isolated from electroporated MLA 1 4 4 cells was analyzed. The probe and the assay have been described.".'
Gel Shift Assay
Crude nuclear extracts were prepared from MLA 144 and Jurkat cells by the Dignam procedure," and used in gel shift assay as described.' Labeling of the double-stranded oligonucleotide probe was obtained by filling in the S' protruding ends of the DNA probe using DNA polymerase large fragment (Klenow) in the presence of dATP, 'ITP, dGTP, and ( U -~~P -~C T P (>3,000 Ci/mmol; New England Nuclear [NEN], Boston, MA) or by phosphorylation of the oligonucleotides at their free S' end hydroxyl group, using polynucleotide kinase and y3'P-ATP (>3,000 Cilmmol; NEN). Labeled probes were purified by gel electrophoresis. When competitor oligonucleotides were used, they were added to the binding reaction 15 minutes before the probe.
Anti-CBF Antibodies
Polyclonal antibodies specific to core binding factor a (CBFa) subunit were raised in rabbits against an amino acid peptide (synthesized by Research Genetics, Huntsville, AL) that spans amino acids 169 to 185 of the protein encoded by the murine homologue of the human acute myeloid leukemia 1 (AML1)
The peptide (CTVDGPREPRRHRQKLDD) also contained an amino-terminal cysteine for thiol-linkage to the carrier protein keyhole limpet hemocyanin (KLH). Coupling was performed using M-maleimidobenzoyl-N-hydeoxysulfosuccinimide ester (Pierce Chemical CO, Rockford, IL). New Zealand rabbits were immunized at multiple intradermal sites (Green Acres Biologicals, Southbridge, MA) with 60 mg peptide coupled to 600 mg KLH in complete Freund's adjuvant. Rabbits were boosted twice at 3 and 6 weeks after the initial immunization in incomplete Freund's adjuvant. Sera were collected after the second boost. Polyclonal specific to the CBF P subunit were generated against a glutathione-S-transferase (GST)-CBFP-22.0 fusion protein.2" Rabbits were immunized and boosted as described above with 1 mg of' GST-CBFP-22.0 protein.
RESULTS
The gibbon MLA 144 cell line produces high level of IL-3 on stimulation' and it has been the system of choice for studies designed at mapping the regulatory sites in the human IL-3
For these reasons, this cell line was initially chosen for in vivo footprinting. To facilitate this study, a 401-bp fragment containing the gibbon IL-3 promoter was cloned by use of the PCR. Consistent with the high degree of conservation between the gibbon and human IL-3 cDNAs: gibbon and human IL-3 promoters are nearly identical ( The proximal region of the IL-3 promoter is important in both the inducible and T-cell-specific expression of IL-3.'
This portion of the promoter contains several regions of interest: ACT-l (or NFIL-3)'"', CK-1 and CK-2/GATA elements," as well as the repeated sequence CACC around -80 that is also found in adult a-and ,&globin promotin the regulation of IL-3 expression'"'; the other sites were recognized on the basis of sequence conservation in cytokine promoters or homology with other known regulatory sites.
To determine whether these sites are contacted in vivo, primers for footprint analysis were chosen to target nt -60 through -190 on the top strand of the gibbon promoter. In vivo methylated DNA was prepared and isolated from unstimulated (U) and stimulated (S) MLA 144 cells.26 DNAs were cleaved with sodium hydroxide as de~cribed,'~ and genomic fragments of the IL-3 promoters were specifically amplified by LMPCR.'2,'3 As a control, protein-free MLA 144 DNA, methylated in vitro (labeled naked, or "N" DNA), was cleaved and processed in parallel with the two DNA samples methylated in vivo (Fig 2A) .
Direct comparison of band intensity between ladders corers.13. [22] [23] [24] Only the ACT-l site has been clearly implicated responding to DNA isolated from unstimulated and stimulated MLA 144 lymphocytes uncovered few differences. However, there were subtle but highly reproducible changes in three regions. Stimulation of IL-3 transcription led to increased protection of CACC repeats centered around nt -83 and -74, of the CK-2/GATA element and of three guanines immediately proximal to ACT-1. In addition, there was a slight protection on stimulation of adenine -149 in the ACT-l site. Surprisingly, a similar analysis of the bottom strand of the gibbon IL-3 promoter using appropriate sets of primers showed only minimal differences in band intensities after T-cell activation (data not shown). The reason for the lack of apparent footprints on the bottom strand is unclear.
To extend the significance of the footprints detected over the top strand of the gibbon E -3 promoter, a specific set of primers (Table l) was used to analyze the human promoter in mock-treated and stimulated Jurkat T cells (Fig 2B) . Again, subtle differences over the CACC (data not shown), the CK-2/GATA element, and the region downstream of ACT-l were reproducibly observed. However, in vivo methylation of guanine -137 in the human L -3 promoter (corresponding to guanine -143 in the gibbon promoter) was unaffected by T-cell stimulation. The footprint over the region corresponding to the CK-1 region observed in Fig 2B was not consistently seen in further experiments, in contrast to the other footprints. As for the gibbon promoter, analysis of the bottom strand of the human promoter was uninformative (data not shown).
The difference in band intensity going from lane "N" to (Fig  2A) . was intriguing because there was no previous indication that this sequence was involved in IL-3 regulation. This was curious because residues in the adjacent regulatory site ACT-I . a known activator involved in the inducible and T-cellspecific expression of IL-3s showed no or little (adenine -149) protection in vivo on activation. Because the differences in hand intensities were reproducibly observed over guanines -142. -143. and -145 ( a site referred to as IF-I l'.'. for in vivo footprint l".') and not ACT-l, we investigated thc specificity of this footprint and the potential role that this region might play in IL-3 regulation.
To determine whether the IF-l",.' footprint was indicative of an additional site in the IL-3 promoter, we synthesized an oligonucleotide probe that spanned the IF-l".' footprint and used it in an in vitro DNA binding assay. A specific complex was observed when nuclear extracts from MLA 144 (Fig 3A) or Jurkat cells were tested (Fig 3B) . The fastermigrating species observed in nuclear extracts from stimulated MLA 144 cells is likely to be the product of proteolysis because variable amount of this complex was detected in independent extracts prepared from stimulated MLA I44 cclls (data not shown). Also. this faster-migrating complex was not observed with extracts from stimulated Jurkat cells (Fig 3B. lane a) . In all cases. binding was specific because it could be competed with excess unlabeled IF-IIL' oligonucleotides. but not by excess ACT-l oligonucleotides ( Fig  3C) . A comparison with thc murine IL-3 promoter indicates the presence of a site homologous to IF-1 l'.' between nucleotides -I28 and -I I2 of that promoter (Table I ).l5 As shown in Fig 3C. the mouse sequence competed as efficiently as human IF-l"-.'. suggesting that IF-I 'l.' is a feature of both promoters.
A search for IF-l""-like sequence in other promoters showed marked homology with the T-cell receptor b (TCR b ) enhancer. and the viral core enhancer elements of polyoma. SV40. and murine sarcoma viruses ( Table I ). To examine whether these sites were related to IF-l".'. corresponding oligonucleotides were tested for their ability to compete u.ith the IF-l".' site using MLA 144 nuclear extracts. As shown in Fig 4A. oligonucleotides corresponding to the IF-l""-like element of polyoma virus" or bE3. the TCR b enhancer site."" compete with the IF-I l'.' probe. In contrast. oligonucleotides corresponding to the SV40 core enhancer or to the unrelated but adjacent site. ACT-l. do not compete. To further examine the requirement for binding specificity. two mutant IF-l".' sites were synthesized. The contacted gua- Table 1 ; ACT-l oligonucleotides have been described.' The fold excess used for each competitor is indicated above each lane. nines identified by in vivo DNA footprinting were changed to cytosines (IF-I"+) and the 3' half of the core sequence in IF-1 'L' was selectively altered to mimic the SV40 enhancer core sequence (IF-IT"') (see Table l ) . These mutants failed to compete for binding to the IF-l".' (Fig 4A) , suggesting that the guanines contacted in vivo and the 3' half are required independently for efficient and specific binding in vitro. To further characterize the complex bound to IF-IIL3, its migration was compared to that detected with a SE3 probe. A complex with similar mobility and exhibiting the same binding specificity was observed (Fig 4B) . Identical results were obtained when the polyoma enhancer sequence (shown in Table I ) was used as a probe instead of IF-IIL3 or SE3 (data not shown).
A
Because a change of the three guanines to cytosines in the IF-I",' sequence abolished binding in vitro, we introduced the same mutation in the human IL-3 promoter. We then tested the effect of this mutation on the expression of a reporter gene directed by two promoter fragments known to mediate expression in activated T cells.'.' Expression of the different constructs was measured by an RNase protection assay.' As previously shown," an IL-3 promoter fragment starting at nucleotide -61 (which includes a TATA box but no other upstream regulatory elements) does not mediate expression of the reporter gene (Fig 5, lane -61) (Fig 5B; compare lanes -61, -143, and -173) .
Interestingly, IF-l"-3 and the SE3 site of the TCR 6 promoter serve similar function: they are not activator sites on their own but are essential for activation." Furthermore, the complex bound by the SE3 or IF-IIL' probe shows similar specificity (Fig 4) , suggesting that the two sites bind the same complex. The 6E3 site is known to bind a heterodimer called CBF."' CBF, also known as the polyomavirus enhancer binding protein 2 (PEPB2). was purified from both calf thymus and Harvey ras transformed NIH 3T3 cells. the p subunit.*'.'" The a subunits share a highly conserved 128-amino acid DNA binding domain also found in a protein encoded by a Drosophila segmentation gene called runt." To demonstrate that IF-l''-3 bound CBF, two different antibodies were used in a gel shift assay. One antibody was raised against a peptide derived from the conserved DNAbinding domain of the CBFa proteins. This antibody should recognize all known members of the family of mouse CBFa proteins and is likely to cross-react with other mammalian CBFas. The other antibody was raised against the mouse CBFP protein, expressed in bacteria as a GST fusion protein.
As shown in Fig 6 (lanes d and e) , addition of either crude CBFa antipeptide antibody or anti-GST-CBF0 fusion protein antiserum affected the amount of complex bound to the IF-1IL3 probe. Simultaneous addition of anti-a and anti-@ CBF antisera disrupted almost completely formation of the complex, whereas addition of a crude control antibody had no significant effect (lanes f, g, and h, respectively). Furthermore, anti-CBF antibodies did not affect binding of other specific complexes to their cognate probes (data not shown). These experiments clearly establish CBF as the binding activity interacting with the IF-IIL3 site.
DISCUSSION
Activated T and NK cells are the only known sources of IL-3 in humans?'.' This remarkable tissue distribution of expression is controlled at the transcriptional level by a series of cis-acting DNA elements found within 300 bp of the start site of the IL-3 gene.')."' This very compactness belies a complexity of interactions between positive and negative sites that is just beginning to be understood. In addition, Cockerill et a13' have identified an inducible, cyclosporinsensitive DNase I hypersensitive region between the IL-3 and GM-CSF genes that contains four NFAT sites." This sequence, when put upstream of a reporter gene driven by the IL-3 promoter, was shown to be a strong enhancer.
As studies of the IL-3 promoter had generally relied on in vitro assays that may not always mimic the in vivo situation, we decided to study the promoter under more physiologic conditions. To this end, we subjected the proximal region of the IL-3 promoter to in vivo footprinting before and after activation of MLA 144 and Jurkat, a gibbon, and human T-cell line, respectively. Because the sequence for the gibbon promoter was unknown, we first cloned the first 401 nucleotides upstream of the IL-3 start site. The gibbon and human promoters show a high degree of sequence conservation. Only 12 differences were observed over the first 401 bp sequenced. The major change is a 6-bp insertion in the gibbon promoter that creates an additional CACC repeat at position -68. This insertion does not appear to play a significant role because the gibbon and human promoters mediate similar levels of expression of reporter genes on transient transfection into MLA 144 cells (data not shown).
In vivo footprint of the proximal region of the IL-3 promoter in MLA 144 and Jurkat cells yielded identical results, even though MLA 144 cells express much higher levels of IL-3. Although the footprints were subtle, the alterations proved to be very reproducible and highly specific. They were observed with several independent MLA 1 4 4 DNA preparations, after 6-or 9-hour stimulation, and with one Jurkat DNA sample (Fig 2B) . The reason for the lack of strong footprints is not clear. It may be technical, and the use of Vent polymerase might help improve the re~olution.'~ Alternatively, cytokine promoters that are turned on and off rapidly may prove difficult to footprint in vivo. Analysis of the IL-2 or IL-4 promoters that share similar characteristics should be informative in that regard. Despite the subtle nature of the observed footprints, their reproducibility led us to investigate whether they might correspond to important regulatory sites. Surprisingly, there was no extensive footprint over ACT-l, the main regulatory site previously identified in this region:"" although the 3' half of ACT-l shows enhanced protection on stimulation. On the other hand, footprints were observed over three regions on the top strand. Two of these had been noted before on the basis of sequence conservation. They included two CACC repeats and the conserved cytokine promoter element CK-2IGATA." The third region mapped just downstream of ACT-1, and had not been implicated in IL-3 regulation.
Outside of the sequence conservation, little is known about the functional role of CACC repeats in the IL-3 promoter. Similar motifs are found in the adult 0-globin promoter. They are required for maximal expression,'4.35 and have been hypothesized to contribute to the effects of the far upstream locus control region. 22 Recently, an erythroid-specific transcription factor that recognizes this repeat has been cloned.76
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The second site, CK-YGATA, is found in the promoters of the IL-3, GM-CSF, and IL-4 genes." Despite its conservation, little evidence has accumulated for a regulatory role of this element in T cells. Although it binds a specific complex in MLA 144 and Jurkat nuclear extracts in vitro (data not shown), CK-2/GATA is dispensable for the activity of the IL-3 promoter, at least in transient expression assays into MLA 144 cells.' The third region identified by in vivo footprinting, IF-IlL3, was somewhat of a surprise. As mentioned, there was no previous indication that it was involved in IL-3 regulation, but because of its immediate vicinity to the known regulatory site ACT-1, its importance might have been overlooked. The footprint occurs over a sequence conserved in the mouse, gibbon, and human IL-3 promoters. Although present in the IL-3 promoter, it is not found in promoters of other cytokines, T-cell specific or not. However, IF-11L3 sequence is related or identical to the viral core enhancers of SV40, polyoma, and Moloney murine leukemia viruses." In addition, analogous sites were described in Tcell-specific promoters like the TCR S chain.26 Mutations in the IF-IIL3 site of the IL-3 promoter indicate that it is absolutely required for IL-3 expression. In fact, IF-1IL' action appears to be mediated via interactions with two distinct sites in the IL-3 promoter. Both the AP-1 and ACT-l sites require a functional IF-llL' site for activation of expression. It is feasible that these interactions occur independently, as a promoter lacking ACT-l but containing AP-1 and IF-11L3 functions nearly as well as its wild-type equivalent.' This is in contrast to the sharp drop in expression mediated by a promoter that is mutated in IF-11L3 but has wild-type AP-1 and ACT-1 sites (Fig 5) . Although IF-lJL' is required, it is not sufficient for expression. A promoter truncated immediately upstream of IF-1IL' and lacking both ACT-l and AP-1 is inactive in stimulated MLA 144 cells. This characteristic helps explain why a linear deletion analysis of the IL-3 promoter performed in earlier studies9~'" had failed to recognize the involvement of this site.
Although we detect a footprint over the IF-1IL3 site in vivo on T- IF-IIL3 and the SE3 site in the TCR S chain promoter are functionally similar. Mutations in the conserved core motif abolish binding in vitro and cripples the activity of their respective promoters in vivo; however, neither site is sufficient for activation of transcription. Furthermore, the two sites share the same binding specificity as judged by competition and gel retardation experiments. In fact, using antibodies directed against CBF, a complex known to bind SE3,26 we were able to show that CBF is also the complex interacting with IF-1IL3. CBF is a heterodimer that was originally described to bind to the Moloney murine leukemia enhancer core motif.27 Recently, Wang et alZo cloned the P-subunit of CBF; interestingly, it does not bind DNA but it functions to stabilize binding of the a-subunit, which is related or identical to AML1, a gene originally identified at the site of the t(8;21) translocation in a class of acute myelogenous leukemia (AML).I9 Similarly, a fusion between CBF-/? and myosin heavy chain results from the pericentric inversion of chromosome 16 associated with AML." Thus, gene fusion involving both CBF chains have been described in the context of AML, suggesting that CBF's activity can be converted to that of an oncogene, at least in myeloid cells. In view of our results, it might be interesting to investigate expression of IL-3 in AML cells associated with rearranged CBF chains, particularly when eosinophilia is also observed such as in M4Eo subtype.
CBF expression is not strictly T-cell specific. We have observed CBF-like complexes in Raji (B cells), U937, and K562 (myeloid cells) nuclear extracts (data not shown). Therefore, it is puzzling that CBF sites have been widely described in promoters of T-cell-specific genes. One possibility is that CBF may preferentially interact with T-cellspecific activators. Alternatively, functional CBF sites may lie immediately adjacent to sites that bind tissue-specific activators. We favor the second hypothesis as we have obtained recent evidence that the function of IF-lIL', which is just next to the ACT-l site in the IL-3 promoter, is strongly position dependent (D.S. Taylor, in preparation).
In summary, in vivo footprinting of the IL-3 promoter has identified a new site, 1F-lrL3, which is critical for IL-3 expression. Despite its conservation in mammalian IL-3 promoters, this site is not found in other cytokine promoters. Involvement of IF-1lL3 had been missed by conventional methods, partly because of its proximity to ACT-l and partly because of its inability to mediate expression on its own. Characterization of its binding specificity and of its functional properties shows that IF-1IL3, like SE3, a site found in the enhancer of the TCR S chain" binds CBF. Although CBF is not T-cell specific, we propose that its role is to further the T-cell tropism of IL-3 expression by interacting with the tissue-specific activator ACT-1.
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